LifeVantage (LFVN) investor relations material

Mission and business overview

• Focuses on wellness and healthy living through science-backed, nutrigenomic products and direct sales.

• Operates in 18 countries with about 110,000 active consumers and a large network of independent consultants.

• 70% of revenue comes from monthly subscriptions, supporting recurring income.

• Maintains a highly variable cost structure and minimal capital requirements.

• Returned $22 million to shareholders since fiscal 2024 via share repurchases and dividends.

Product innovation and portfolio

• Offers patented products like Protandim Nrf2 Synergizer, TrueScience Liquid Collagen, and MindBody GLP-1 System.

• Acquired LoveBiome, expanding into the microbiome health sector with the P84 product.

• Product stacks and subscriptions provide synergistic health benefits and higher consumer retention.

• Products are supported by peer-reviewed research and a scientific advisory board.

• Focus on activating wellness through unique, science-based formulas that work with individual biology.

Market position and growth

• Operates in 6 of the top 10 global direct selling markets, with the US accounting for 78% of sales.

• Gut health market is a major focus, projected to reach $32.4 billion by 2035 with an 8.4% CAGR.

• Fiscal 2025 revenue reached $229 million, with adjusted EBITDA of $22 million (9.7% margin).

• Clean balance sheet, debt-free, and $12.5 million in cash as of March 2026.

• New product launches and compensation plan updates drive consultant engagement and international expansion.